Details of the Drug Combination

General Information of Drug Combination (ID: DCPE739)

Drug Combination Name
Grazoprevir Elbasvir
Indication
Disease Entry Status REF
Hepatitis C Phase 1 [1]
Component Drugs Grazoprevir   DM9BPLW Elbasvir   DMJLE18
N.A. N.A.
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Grazoprevir
Disease Entry ICD 11 Status REF
Hepatitis C 1E51 Approved [2]
Grazoprevir Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Indication(s) of Elbasvir
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Elbasvir Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
HCV-1 and HCV-4 infection DCDBNYX N. A. Approved [6]
Hepatitis C DCEMB4N N. A. Phase 2 [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01717326) A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19. April 21, 2020.
4 FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.
5 Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.
6 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
7 ClinicalTrials.gov (NCT02332707) Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)